Aldafermin Market Sales

Key Factors Driving Aldafermin Growth

• Strong anti-fibrotic and liver fat reduction activity in MASH/NASH

Aldafermin has demonstrated clinically meaningful reductions in liver fat and fibrosis biomarkers across multiple Phase II studies. In a 24-week Phase II trial published in Gastroenterology, Aldafermin achieved a 7.7% absolute reduction in liver fat content versus 2.7% with placebo (p=0.002). Additionally, 38% of treated patients achieved ≥1-stage fibrosis improvement without worsening of NASH compared with 18% on placebo. These results support its potential as a disease-modifying therapy in patients with F2–F3 fibrosis.

• Differentiated FGF19 mechanism supports combination and niche positioning

Aldafermin works through FGF19-mediated regulation of bile acid synthesis, lipid metabolism, and glucose homeostasis. Unlike GLP-1 agonists that primarily target weight loss, Aldafermin directly suppresses bile acid synthesis and fibrogenesis. Studies showed significant reductions in toxic hydrophobic bile acids and fibrosis marker Pro-C3, suggesting broader anti-fibrotic activity across metabolic and cholestatic liver diseases. This differentiated biology may allow Aldafermin to remain relevant either in combination regimens or in fibrosis-focused patient populations.

• Large and growing MASH patient population creates substantial market opportunity

MASH/NASH affects tens of millions globally, with estimates suggesting more than 16 million patients in the United States alone have clinically significant disease. Rising obesity, diabetes, and metabolic syndrome prevalence continue to expand the addressable market. Even modest penetration into patients with advanced fibrosis could support substantial commercial revenue for effective anti-fibrotic therapies like Aldafermin.

• Potential use beyond MASH, including PSC and cholestatic diseases

Aldafermin has also shown activity in primary sclerosing cholangitis (PSC) and other cholestatic liver disorders through potent suppression of cytotoxic bile acids. Because PSC remains an area with very limited approved pharmacologic options, expansion into cholestatic liver diseases could diversify the commercial opportunity and reduce dependence on the highly competitive MASH segment.

Increasing validation of the FGF pathway strengthens investor and industry confidence

Recent clinical successes of other FGF-based therapies, especially FGF21 analogues such as efruxifermin, have increased confidence in the broader FGF therapeutic class for MASH. Positive fibrosis reversal data from Akero Therapeutics’ late-stage FGF21 programs have reinforced industry belief that endocrine fibroblast growth factors can meaningfully reverse liver fibrosis, indirectly benefiting perception of Aldafermin’s FGF19 platform. 

Aldafermin Recent Developments

• In January 2024, NGM Biopharmaceuticals, a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced encouraging new data from an ongoing Phase I Part 1b study evaluating NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab). NGM Bio also outlined its strategy to evolve clinical development of its product candidates aldafermin and NGM120 to focus on rare conditions characterized by significant unmet need.  

“Aldafermin Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Aldafermin for potential indication like Primary sclerosing cholangitis, Diarrhea, Non-alcoholic steatohepatitis, and Primary biliary cirrhosis in the 7MM. A detailed picture of Aldafermin’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Aldafermin for potential indications. The Aldafermin market report provides insights about Aldafermin’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Aldafermin performance, future market assessments inclusive of the Aldafermin market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Aldafermin sales forecasts, along with factors driving its market.

Aldafermin Drug Summary

Aldafermin (NGM282) is an engineered analog of fibroblast growth factor 19 (FGF19) developed by NGM Bio for the treatment of liver and metabolic diseases, particularly nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC). Designed to retain the metabolic and bile acid–regulating properties of native FGF19 while minimizing tumorigenic potential, aldafermin acts by binding to the FGFR4/β-Klotho receptor complex in the liver, thereby suppressing bile acid synthesis through downregulation of CYP7A1, reducing hepatic inflammation, fibrosis, and steatosis. Administered as a once-daily subcutaneous injection, the drug has demonstrated significant reductions in liver fat content, fibrosis biomarkers, and serum bile acid levels in multiple Phase II clinical studies. Aldafermin has also shown potential benefits in improving liver histology and metabolic parameters, although gastrointestinal adverse events such as diarrhea and abdominal discomfort have been commonly reported. Its differentiated mechanism targeting bile acid metabolism and fibrosis pathways has positioned aldafermin as a promising investigational therapy in chronic cholestatic and fibrotic liver diseases. The report provides Aldafermin’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

 

Scope of the Aldafermin Market Report

The report provides insights into:

• A comprehensive product overview including the Aldafermin MoA, description, dosage and administration, research and development activities in potential indication like Primary sclerosing cholangitis, Diarrhoea, Non-alcoholic steatohepatitis, and Primary biliary cirrhosis.
• Elaborated details on Aldafermin regulatory milestones and other development activities have been provided in Aldafermin market report.
• The report also highlights Aldafermin‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Aldafermin market report also covers the patents information, generic entry and impact on cost cut.
• The Aldafermin market report contains current and forecasted Aldafermin sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Aldafermin market report also features the SWOT analysis with analyst views for Aldafermin in potential indications.

Methodology

The Aldafermin market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

Aldafermin Analytical Perspective by DelveInsight

In-depth Aldafermin Market Assessment

This Aldafermin sales market forecast report provides a detailed market assessment of Aldafermin for potential indication like Primary sclerosing cholangitis, Diarrhoea, Non-alcoholic steatohepatitis, and Primary biliary cirrhosis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Aldafermin sales data uptil 2034.

 

Aldafermin Clinical Assessment

The Aldafermin market report provides the clinical trials information of Aldafermin for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Aldafermin Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Aldafermin Market Potential & Revenue Forecast

• Projected market size for the Aldafermin and its key indications
• Estimated Aldafermin sales potential (Aldafermin peak sales forecasts)
• Aldafermin Pricing strategies and reimbursement landscape

 

Aldafermin Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Aldafermin Market positioning compared to existing treatments
• Aldafermin Strengths & weaknesses relative to competitors

 

Aldafermin Regulatory & Commercial Milestones

• Aldafermin Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

 

Aldafermin Clinical Differentiation

• Aldafermin Efficacy & safety advantages over existing drugs
• Aldafermin Unique selling points

 

Aldafermin Market Report Highlights

• In the coming years, the Aldafermin market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Aldafermin companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Aldafermin’s dominance.
• Other emerging products for Primary sclerosing cholangitis, Diarrhoea, Non-alcoholic steatohepatitis, and Primary biliary cirrhosis are expected to give tough market competition to Aldafermin and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Aldafermin in potential indications.
• Analyse Aldafermin cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Aldafermin sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Aldafermin in potential indications.

 

Key Questions Answred In The Aldafermin Market Report:

• What is the class of therapy, route of administration and mechanism of action of Aldafermin? How strong is Aldafermin’s clinical and commercial performance?
• What is Aldafermin’s clinical trial status in each individual indications such as Primary sclerosing cholangitis, Diarrhoea, Non-alcoholic steatohepatitis, and Primary biliary cirrhosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Aldafermin Manufacturers?
• What are the key designations that have been granted to Aldafermin for potential indications? How are they going to impact Aldafermin’s penetration in various geographies?
• What is the current and forecasted Aldafermin market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Aldafermin in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 
• What are the other emerging products available and how are these giving competition to Aldafermin for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Aldafermin? What is the duration of therapy and what are the geographical variations in cost per patient?